Table 3.
Subgroup analysis of treatments associated with mortality for those without a diagnosis of MIS-C.
| Treatment | Mortality |
Logistic Regression |
||
|---|---|---|---|---|
| With Treatment | Without Treatment | Odds Ratio | 95% CI | |
| Patients without MIS-Ca | ||||
| Day 1 HFNC | 3/57 (5·3%) | 47/308 (15%) | 0·31 | 0·09, 1·03 |
| Day 1 NIV | 3/42 (7·1%) | 46/321 (14% | 0·46 | 0·14, 1·55 |
| Day 1 IMV | 26/108 (24%) | 24/256 (9·4%) | 3·07 | 1·67, 5·64 |
| Day 1 Vasopressors | 27/111 (24%) | 23/251 (9·2%) | 3·19 | 1·73, 5·86 |
| Day 1 Neuromuscular Blockade | 9/37 (24%) | 40/325 (12·3%) | 2·29 | 1·01, 5·20 |
| Day 1 Prone Position | 4/10 (40%) | 44/351 (13%) | 4·65 | 1·26, 17·1 |
| Day 1 Renal Replacement | 4/13 (31%) | 46/348 (13%) | 2·92 | 0·86, 9·86 |
| Hospital Medications | ||||
| Corticosteroids | 31/234 (13%) | 19/133 (14%) | 0·92 | 0·50, 1·70 |
| Dexamethasone | 16/135 (12%) | 34/233 (15%) | 0·79 | 0·42, 1·49 |
| Methylprednisolone | 10/90 (11%) | 40/278 (14%) | 0·74 | 0·36, 1·56 |
| IVIG | 8/96 (8·3%) | 42/272 (15%) | 0·50 | 0·22, 1·10 |
| IVIG and methylprednisolone | 3/34 (8·8%) | 47/334 (14%) | 0·59 | 0·17, 2·01 |
| IVIG or methylprednisolone | 15/151 (9·9%) | 35/217 (16%) | 0·57 | 0·30, 1·09 |
| Any Anticoagulation | 12/141 (8·5%) | 38/227 (17%) | 0·46 | 0·23, 0·92 |
| Prophylactic Anticoagulation | 10/117 (8·6) | 40/251 (16%) | 0·49 | 0·24, 1·02 |
| Convalescent Plasma | 2/11 (18%) | 48/357 (13%) | 1·43 | 0·30, 6·82 |
| Hydroxychloroquine/Chloroquine | 4/15 (27%) | 46/353 (13%) | 2·43 | 0·74, 7·94 |
Statistically significant results in bold.
a
Excluded antiplatelet medications and anakinra in the non-MISC subgroup due to low numbers receiving the treatment.